Royalty Pharma plc

RPRX

$58.52

Updated: 23/09/2026, 14:38:48

Market Cap

$25.94B

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Country

Stock valuation chart

One-year closing share-price history for RPRX

Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

USD

NASDAQ

CEO: Pablo Legorreta

Employees: 100

https://www.royaltypharma.com

Asset Summaries

Latest generated summaries for RPRX

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for RPRX.

Share price: $58.52
Market cap: $25.94B
Exchange: NASDAQ
Currency: USD
CEO: Pablo Legorreta
Employees: 100
IPO date: 16/06/2020
Beta: 0.43
Last dividend: $0.00
Day range: $57.86 – $59.03
52-week range: $34.63 – $64.38
1-day performance: 0.14%
1-year performance: 68.99%
Current drawdown (1Y): -9.10%
CIK: 0001802768
CUSIP: G7709Q104
ISIN: GB00BMVP7Y09
Created: 07/12/2025, 14:02:46
Last update: 23/09/2026, 14:38:48

Track Royalty Pharma plc with an AI analyst

See which prediction-market events move RPRX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to RPRX from your Railway `news_articles` table.

Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 09/06/2026, 20:22:13

Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 19/05/2026, 14:50:42

Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead

Seeking Alpha • STOCK • 16/05/2026, 05:12:44

Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 13/05/2026, 18:10:51

RPRX vs. AMGN: Which Stock Is the Better Value Option?

Zacks Investment Research • STOCK • 06/05/2026, 14:41:12

Royalty Pharma plc (RPRX) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 06/05/2026, 13:41:17

Royalty Pharma PLC (RPRX) Hit a 52 Week High, Can the Run Continue?

Zacks Investment Research • STOCK • 06/05/2026, 12:15:46

Royalty Pharma reports first quarter 2026 results

GlobeNewsWire • STOCK • 06/05/2026, 09:00:00

Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026

GlobeNewsWire • STOCK • 15/04/2026, 18:15:00

Can Royalty Pharma (RPRX) Keep the Earnings Surprise Streak Alive?

Zacks Investment Research • STOCK • 14/04/2026, 15:11:23

Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

GlobeNewsWire • STOCK • 30/03/2026, 09:15:00

Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence

GlobeNewsWire • STOCK • 23/03/2026, 08:15:00